Home > Healthcare > Pharmaceuticals > Finished Drug Form > Interleukin Inhibitors Market

Interleukin Inhibitors Market Share

Report ID: GMI10044
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Interleukin Inhibitors Market Share

The interleukin inhibitors industry is characterized by intense competition, with companies focusing on extensive R&D investments, strong product portfolios, and strategic collaborations. New entrants and smaller biopharmaceutical companies are also contributing to the market dynamics with innovative therapies and niche applications. Also, continuous advancements in biologic treatments and precision medicine, along with robust clinical pipelines, drive competition. Additionally, the expanding indications for interleukin inhibitors and increasing approvals by regulatory authorities further intensify the competitive landscape.

Interleukin Inhibitors Market Companies

Few of the prominent players operating in the interleukin inhibitors industry include:

AbbVie Inc.
Biogen
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Fujifilm Kyowa Kirin Biologics Co., Ltd.
Genentech USA, Inc.
Janssen Pharmaceutical Companies (Johnson and Johnson)
Novartis AG
Regeneron Pharmaceuticals, Inc.
Samsungbioepis Co,.Ltd.
Sanofi
Sobi, Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Industries Ltd.
UCB S.A

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Interleukin inhibitors industry size was worth USD 24.3 billion in 2023 and will grow at a 12% CAGR between 2024 and 2032, driven by escalating incidences of autoimmune disorders like rheumatoid arthritis and psoriasis.

The psoriasis segment will record 11.9% CAGR through 2032, primarily due to increasing prevalence of the chronic skin condition and ongoing research into the immunopathogenesis of psoriasis.

U.S. interleukin inhibitors industry achieved USD 9.3 billion in 2023, propelled by the region's advanced healthcare infrastructure and rise in research and development activities.

Some of the prominent interleukin inhibitors industry players are AbbVie Inc., Biogen, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Fujifilm Kyowa Kirin Biologics Co., Ltd., Genentech USA, Inc., Janssen Pharmaceutical Companies (Johnson and Johnson), Novartis AG, Regeneron Pharmaceuticals, Inc., and Sanofi, among others.